Novo escalates M&A: $10B Metsera bid and $240M Omeros zaltenibart deal
Key Questions
What is Novo's deal with Metsera?
Novo Nordisk topped Pfizer's $8.1B bid with a $10B offer for Metsera amid a court fight. This escalates M&A to bolster its pipeline beyond obesity drugs.
What are the details of the Omeros acquisition?
Novo added Omeros' zaltenibart, a MASP-3 immunology asset, for $240M upfront and up to $2.1B total. It diversifies Novo's portfolio versus Lilly's GLP-1 focus.
Why is Novo pursuing these M&A deals?
The acquisitions aim to diversify beyond obesity/GLP-1 amid competition. Omeros benefits from the deal and YARTEMLEA launch, turning a corner per analysts.
Tops Pfizer $8.1B for Metsera; Omeros zaltenibart (MASP-3, $240M/$2.1B) Q4'25 $237.6M gain/$86.5M net, OMER +14%/5% AH, Yartemlea launch/FDA-approved, Hold/Mod Buy $40PT—diversifies GLP-1.
Sources (2)
Updated Apr 8, 2026